Related Experiment Video
Updated: May 29, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Insulin therapy during hospitalization
Anestis Zantidis1, Fotios Iliadis, Triantafillos Didangelos
1Diabetes Division, 1st Propeudetic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece.
Diabetes Research and Clinical Practice
|August 26, 2011
Summary
Hospital hyperglycemia management is complex, as it can worsen outcomes but aggressive treatment risks hypoglycemia. Tailored glycemic goals for different patient groups are recommended.
Area of Science:
- Internal Medicine
- Endocrinology
- Clinical Management
Background:
- Hospital hyperglycemia is prevalent in diabetic and non-diabetic patients.
- Historically viewed as a marker of acute illness, it's now linked to poorer prognosis and increased mortality.
- Emerging evidence questions this direct link and highlights risks of hypoglycemia from treatment.
Purpose of the Study:
- To review current understanding of hospital hyperglycemia.
- To discuss evolving treatment strategies and their associated risks.
- To propose a patient-group-specific approach to glycemic control in hospitalized individuals.
Main Methods:
- Literature review of clinical studies on hospital hyperglycemia.
- Analysis of data on prognosis and mortality related to hyperglycemia and hypoglycemia.
- Categorization of hospitalized patients into distinct management groups.
Main Results:
- Hyperglycemia during hospitalization is associated with aggravated prognosis and increased mortality.
- Intensive treatment of hyperglycemia carries a risk of hypoglycemia, potentially increasing mortality.
- No universal consensus exists on optimal management strategies.
Conclusions:
- A one-size-fits-all approach to hospital hyperglycemia is inappropriate.
- Differentiated glycemic targets and management plans are necessary for various patient cohorts.
- Patient stratification includes intensive care unit (ICU) and non-ICU patients (general and cardiac), and peri-operative individuals.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...